RX Biosyent Inc

BioSyent Inc.  ("BioSyent") (TSX VENTURE:RX) is pleased to announce that its
subsidiary BioSyent Pharma Inc. has signed an exclusive Licensing and
Distribution Agreement with a European partner for two new products that will be
marketed by its' Hospital Products Division. The products utilize a patented
delivery system which will provide Canadian hospitals and healthcare
professionals improved safety and cost effectiveness versus products currently
in use. The products will be launched after Health Canada approval.


BioSyent Inc. continues to concentrate on its pharmaceutical strategy to source
products that have been successfully developed and proven to be safe and
effective; manage these products through the regulatory process and product
registration (approval); and once approved, market these products in Canada. The
Company is focused on medications that occupy a niche in the market, that are
unique either due to complexity of manufacture or provide novel technological or
therapeutic advantages, or that are backed by strong partners holding
intellectual property rights that are defendable. This strategy allows the
Company to market these medications as brands owned by, or licensed to, it.


BioSyent Inc. is a publicly traded specialty pharmaceutical company whose wholly
owned subsidiary, BioSyent Pharma Inc., sources, acquires or in-licences
pharmaceutical products and markets these products in Canada. Wholly owned
BioSyent subsidiary Hedley Technologies Ltd. operates the company's legacy
business marketing bio and health friendly non-chemical insecticides. BioSyent
common shares are listed for trading on the TSX Venture Exchange (TSXV) under
the symbol RX.

Biosyent (TSXV:RX)
Historical Stock Chart
From Oct 2024 to Nov 2024

Biosyent (TSXV:RX)
Historical Stock Chart
From Nov 2023 to Nov 2024